David Charytan, MD, MSc, of NYU Grossman School of Medicine, discusses the two most important risk factors when assessing patients with autosomal-dominant polycystic kidney disease. (0:43 ...

Dear D.B.: This is a very touching story, and I hope to help readers understand a few points. Autosomal dominant polycystic ...

A team of 10 U.S.-based investigators delved deeper into how autosomal dominant polycystic kidney disease affects patients’ health-related quality of life and pain levels. Here’s what they found.

Autosomal dominant polycystic kidney disease (ADPKD) is the most common, potentially lethal genetic disorder characterized by the progressive enlargement of numerous fluid-filled cysts and the ...

Buoyed by encouraging data for its lead drug for autosomal dominant polycystic kidney disease, Regulus Therapeutics has moved swiftly to file a financing that will give it the finances needed to ...

Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Regulus (RGLS – Research Report) and keeping the price target at ...

Table 1. Landesman and Scherr's classifications of pregnant patients with autosomal dominant polycystic kidney disease, based on the degree of severity of their renal disease. Group A ...

This improvement is reflected in increased urine output, reduced levels of urea and creatinine, and an overall enhancement in the patient's quality of life as measured by the WHO's quality of life ...

I currently hold the title of Senior Research Fellow in Nephrology. Research interests Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic disease affecting the kidney ...

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative ...